Last updated: March 2, 2026
What is NDC 00406-1236?
NDC 00406-1236 refers to Vasopressin Injection, USP. It is a synthetic hormone used for vasoconstriction in conditions such as vasodilatory shock, cardiac arrest, and diabetes insipidus. The drug is marketed by Teva Pharmaceuticals and has both hospital and emergency use indications.
Market Overview
Current Market Size
The global vasopressin market was valued at approximately USD 250 million in 2022. It has experienced consistent growth at a compound annual growth rate (CAGR) of about 4.5% over the last five years.[1]
Market Drivers
- Increasing incidence of shock-related conditions, including septic shock.
- Preference for vasopressin as a second-line vasoconstrictor.
- Expanding indications in critical care.
Competitive Landscape
Major competitors include:
- Ferring Pharmaceuticals (Vasostrict)
- Sanofi (Vasopressin)
- Mauthner Pharma (generic versions)
- Various generic manufacturers
Market share is distributed among brand products (e.g., Vasostrict by Ferring) and generics, with generics accounting for 60-70% of sales due to price competition.
Regulatory Status
- US: Approved by the FDA for vasodilatory shock and cardiac arrest.
- International: Approved in Europe and Asia under different brand names.
Pricing Factors
- Hospital procurement contracts.
- Wholesaler discounts.
- Physician office and emergency procurement policies.
Price Projections
Current Pricing
As of Q1 2023, average wholesale acquisition cost (AWAC) per vial is around USD 45–55, with hospital procurement prices averaging USD 40–50 per vial.[2]
Historical Trends
- Since FDA approval, the price has remained relatively stable, with minor fluctuations.
- The entry of generics in recent years has decreased average prices by approximately 15–20%.
Future Price Trends (Next 3–5 Years)
Factors influencing future pricing:
- Increased generic competition: May lead to a further 10–15% decrease in prices.
- Supply chain disruptions: Could temporarily increase prices.
- Policy shifts: Potential reimbursement reforms could impact hospital procurement policies.
Projected Price Range (2023-2028):
| Year |
Estimated Price Per Vial (USD) |
Notes |
| 2023 |
40–55 |
Current market prices. |
| 2024 |
36–50 |
Slight decline due to increased generics. |
| 2025 |
34–47 |
Continued competition, supply chain normalization. |
| 2026 |
32–45 |
Potential plateau, barring major policy changes. |
| 2027 |
30–43 |
Stabilization expected; prices reach pre-generic levels. |
Distribution & Supply Chain Insights
- Majority of procurement occurs via hospital systems directly from manufacturers and distributors.
- Bulk purchasing agreements influence downward pricing.
- Supply chain disruptions, like raw material shortages, can temporarily shift prices.
Strategic Outlook
- Market growth remains steady, driven by increased critical care needs.
- Price erosion expected as generics gain market share.
- Regulatory pressures may influence pricing strategies, with potential shifts towards value-based pricing models.
Key Takeaways
- The current market size for vasopressin injection (NDC 00406-1236) is approximately USD 250 million globally.
- Average prices range from USD 40–55 per vial, with a declining trend anticipated due to increased generic competition.
- Price declines of 10–15% over the next five years are forecasted, assuming typical market dynamics.
- Supply chain and policy factors could introduce variability in prices.
- The critical care market's growth sustains demand despite price pressures.
FAQs
What factors could prevent price declines in vasopressin?
Limited generic supply, raw material shortages, regulatory restrictions, and supply chain disruptions.
How does competition from generics influence the market?
Generics capture an increasing share, leading to price erosion of 10–20% over five years.
Are there upcoming regulatory changes that could impact pricing?
Potential reimbursement reforms and policy shifts toward value-based care could influence procurement strategies.
How does hospital purchasing behavior affect prices?
Bulk contracts and direct negotiations substantially lower prices compared to retail or smaller institutional purchases.
What are key growth opportunities for vasopressin over the next five years?
Expansion into new geographic markets, new indications, and formulations (e.g., nasal spray) could drive growth.
References
- MarketsandMarkets. (2022). Vasopressin Market by Application, Distribution Channel, and Region.
- IQVIA. (2023). U.S. Hospital Procurement Data.
